This September marks a meaningful milestone: four years since the announcement of the planned merger that eventually united three companies and businesses into what we now proudly call Uniogen.

---

What began as a bold vision to bring together innovative Finnish biotech and life science companies and university spin-offs has since grown into a unified organization with a shared mission: advancing diagnostics and improving lives through cutting-edge innovations and collaboration.

What has truly distinguished our journey is the spirit of collaboration that has flourished within our teams. Over the past few years, our industry has faced a fair share of challenges, and the team has consistently shown adaptability and dedication. Every Uniogen employee has played a vital role in our progress, and it is their efforts that continue to drive us forward.

We know there is much to learn and achieve, but we’re excited for the journey ahead and grateful to be shaping the future of diagnostics. Together.

– Uniogen Team

---

From Three to One

In 2021 a new legal entity, Uniogen, was founded and we set out to combine our strengths in immunoassays, molecular diagnostics, and laboratory instrumentation. Thanks to the shared values, similar cultures, and long-standing professional connections between the three companies, the transition felt less like a formal process and more like coming together to get things done as one team. While big multi-year projects such as aligning quality management systems, implementing new IT and ERP systems, and harmonizing operations have been complex, our team has made tremendous progress in building a shared foundation that supports our operational excellence.

Highlights

We’ve experienced both highs and lows, celebrating new product milestones while also making the decision to retire some long-standing offerings to bring focus on our new product development. Change has been constant and so has progress. During the past four years we have, for example:

🎯 Successfully created a strong, unified brand
With a distinctive visual identity that stands out in the industry and is now recognized by peers and competitors alike around the world.

🧪 Made strong progress in product development
Particularly with our ovarian cancer test , now available as a Research Use Only (RUO) product. According to our data, the ovarian cancer assay detects significantly more early-stage ovarian cancer cases compared to the standard CA 125 test. At the same time, our Upcon™ labeling technology continues to demonstrate exceptional sensitivity and stability in various applications.

🤝 Established new partnerships
With companies such as Lumito , who are now utilizing Upcon particles in their own products, marking an exciting step forward in bringing our innovations into real-world use.

🔬 Invested heavily in R&D
Expanding our IP portfolio with new patents that protect our most advanced technologies. A key focus has been early cancer detection, where we’ve streamlined operations to accelerate development and prepare our applications for broader clinical and commercial use. Our oncology portfolio alone now has a total of 17 patents or patent applications in 4 different patent families. They are supported by 9 technology patent families, comprised of 26 patents/patent applications which enable the development of ultra-sensitive tests and measurement systems.

🛠️ Focused our CDMO and OEM services
Supporting partners in bringing their diagnostic and life science innovations to market. By harnessing our expertise and offering tailored solutions such as custom components, white-label products, or co-development projects, we’ve become a trusted extension of our partners’ teams. This trust has consistently been reflected in the excellent Net Promoter Scores we’ve continued to achieve in our customer satisfaction surveys year after year.

🎓 Continued working closely with universities and universities of applied sciences
To advance research, co-develop new technologies, and support the next generation of biotech professionals. These partnerships have enriched our R&D efforts and helped bridge the gap between academic discovery and real-world application. Whether through joint research projects, student internships, or technology validation, these collaborations continue to play a vital role in shaping our future.

🌍 Participated in major industry events 
Both within Finland and around the world. These events have been invaluable opportunities to share our innovations, stay connected with the diagnostics and life science community, and spark new collaborations, which is something we look forward to continuing in the years ahead.

Looking Ahead

As we celebrate this anniversary, we remain focused on the future. We’re excited about the innovations on the horizon, the partnerships we’ll continue to build, and the impact we’ll make together. Thank you for being part of our journey.

Here’s to the next chapter!